CA
NZ
UK
AU
IND
US
…
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is based in Kingsgrove, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cyclopharm Ltd develops and supplies Technegas, a diagnostic system and single-use consumables for lung ventilation imaging in nuclear medicine.
Long-term growth may be driven by broader clinical adoption, higher prevalence of respiratory disease and recurring consumable sales from an expanding installed base, and investors may find it attractive for its consumable-led revenue model and focused niche in pulmonary diagnostics.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -17.86M | -13.07M | -4.19M | -6.03M | -4.35M |
| Net income | -17.22M | -13.20M | -4.70M | -6.61M | -5.04M |
| Selling general administrative | - | 21.48M | 14.00M | 10.96M | 10.30M |
| Selling and marketing expenses | - | 3.15M | 2.05M | 2.92M | 1.02M |
| Gross profit | -1.46M | 17.93M | 16.08M | 15.78M | 12.66M |
| Reconciled depreciation | - | 1.48M | 0.94M | 0.93M | 0.76M |
| Ebit | -18.18M | -14.52M | -4.77M | -5.96M | -4.33M |
| Ebitda | -16.41M | -13.69M | -3.84M | -5.03M | -3.57M |
| Depreciation and amortization | 1.77M | 0.83M | 0.94M | 0.93M | 0.76M |
| Operating income | -18.18M | -14.35M | -5.26M | -5.96M | -4.33M |
| Other operating expenses | 50.51M | 41.92M | 36.36M | 30.85M | 24.66M |
| Interest expense | 0.63M | 0.32M | 0.22M | 0.07M | 0.02M |
| Tax provision | - | 0.13M | 0.51M | 0.58M | 0.69M |
| Interest income | - | 0.67M | 0.49M | 0.11M | 0.09M |
| Net interest income | - | 0.35M | 0.27M | -0.16M | -0.09M |
| Income tax expense | -0.64M | 0.13M | 0.51M | 0.58M | 0.69M |
| Total revenue | 32.33M | 27.57M | 26.34M | 23.22M | 17.70M |
| Total operating expenses | 16.72M | 32.28M | 13.72M | 23.41M | 19.61M |
| Cost of revenue | 33.78M | 9.64M | 22.64M | 7.44M | 5.04M |
| Total other income expense net | 0.33M | 1.45M | 5.84M | -0.07M | -0.02M |
| Net income from continuing ops | - | -13.20M | -4.70M | -6.61M | -5.04M |
| Net income applicable to common shares | - | -13.20M | -4.70M | -6.61M | -5.04M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 46.10M | 62.13M | 45.91M | 49.54M | 55.74M |
| Intangible assets | 1.70M | 4.18M | - | 4.57M | 4.56M |
| Other current assets | 1.81M | 2.43M | 0.45M | 0.57M | 0.39M |
| Total liab | 18.99M | 19.40M | 13.65M | 13.01M | 12.67M |
| Total stockholder equity | 27.11M | 42.73M | 32.26M | 36.54M | 43.07M |
| Deferred long term liab | - | - | - | 0.79M | 0.79M |
| Other current liab | 6.64M | 6.19M | 5.27M | 3.33M | 5.07M |
| Common stock | 87.07M | 92.41M | 63.78M | 63.42M | 62.97M |
| Capital stock | - | - | - | 63.42M | 62.97M |
| Retained earnings | -65.08M | -47.86M | -34.66M | -29.07M | -21.58M |
| Other liab | - | - | - | 0.95M | 0.92M |
| Good will | 0.97M | 0.93M | 0.90M | 0.87M | 0.87M |
| Other assets | - | - | 0.00M | 0.64M | 1.61M |
| Cash | 6.63M | 20.57M | 11.73M | 20.30M | 29.25M |
| Total current liabilities | 11.26M | 10.61M | 8.67M | 7.94M | 7.42M |
| Current deferred revenue | - | - | 0.04M | - | - |
| Net debt | 8.29M | -12.28M | -7.50M | -15.96M | -24.74M |
| Short term debt | 0.56M | 0.63M | 0.21M | 0.21M | 0.18M |
| Short long term debt total | 14.92M | 8.29M | 4.23M | 4.33M | 4.51M |
| Other stockholder equity | - | -0.00M | - | -1.05M | -3.66M |
| Property plant equipment | - | - | - | 6.60M | 6.25M |
| Total current assets | 28.46M | 42.39M | 30.20M | 36.87M | 43.25M |
| Net tangible assets | - | - | - | 31.89M | 38.43M |
| Short term investments | - | 1.23M | - | - | - |
| Net receivables | 8.59M | 4.91M | 7.90M | 7.71M | 8.04M |
| Inventory | 11.43M | 13.25M | 10.12M | 8.29M | 5.51M |
| Accounts payable | 4.06M | 3.80M | 3.15M | 4.40M | 2.17M |
| Accumulated other comprehensive income | 5.11M | -1.82M | 3.14M | 2.19M | 1.67M |
| Non currrent assets other | - | 1.53M | 0.03M | - | - |
| Non current assets total | 17.64M | 19.74M | 15.72M | 12.67M | 12.49M |
| Capital lease obligations | - | - | - | 4.33M | 4.51M |
| Long term debt total | - | - | - | 4.12M | 4.33M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.97M | -0.51M | -1.55M | -1.16M |
| Change to liabilities | - | - | - | 1.08M | 1.82M |
| Total cashflows from investing activities | 3.00M | -0.97M | -0.51M | -1.55M | -1.16M |
| Net borrowings | - | - | - | -0.29M | -0.29M |
| Total cash from financing activities | -1.12M | 22.22M | -1.02M | -0.73M | 30.17M |
| Change to operating activities | - | - | - | 0.74M | 0.02M |
| Net income | -17.22M | -13.20M | -4.70M | -6.61M | -5.04M |
| Change in cash | -13.94M | 8.84M | -8.57M | -8.95M | 27.37M |
| Begin period cash flow | 20.57M | 11.73M | 20.30M | 29.25M | 1.87M |
| End period cash flow | 6.63M | 20.57M | 11.73M | 20.30M | 29.25M |
| Total cash from operating activities | -17.33M | -12.57M | -7.20M | -5.68M | -1.63M |
| Issuance of capital stock | - | 24.00M | - | - | 33.00M |
| Depreciation | 1.77M | 1.48M | 0.94M | 0.93M | 0.76M |
| Other cashflows from investing activities | - | -0.17M | -0.30M | - | 0.00M |
| Dividends paid | - | 0.00M | -0.88M | -0.88M | -0.88M |
| Change to inventory | -0.81M | -3.09M | -1.86M | -2.78M | -0.78M |
| Change to account receivables | -1.69M | 0.24M | -0.49M | -0.59M | 0.69M |
| Sale purchase of stock | - | -1.14M | - | 0.00M | -1.66M |
| Other cashflows from financing activities | -1.12M | 0.01M | 0.14M | 0.16M | -0.29M |
| Change to netincome | - | - | - | 0.52M | 0.75M |
| Capital expenditures | 1.99M | 0.97M | 0.54M | 1.55M | 1.16M |
| Change in working capital | -2.85M | -2.61M | -1.93M | 0.45M | 0.40M |
| Stock based compensation | - | 0.36M | 0.52M | - | - |
| Other non cash items | 0.97M | 1.75M | -0.98M | 5.68M | 4.28M |
| Free cash flow | -19.32M | -13.55M | -7.74M | -7.23M | -2.79M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CYC Cyclopharm Ltd |
-0.01 2.15% |
0.46 | - | 116.28 | 1.66 | 1.93 | 3.23 | -24.57 |
| COH Cochlear Ltd |
1.03 0.67% |
155.47 | 68.64 | 27.40 | 4.30 | 5.34 | 3.97 | 28.09 |
| IMR Imricor Medical Systems Inc |
-0.03 2.29% |
1.28 | - | - | 36401.21 | 17.45 | 4019.33 | -2.60 |
| AVR Anteris Technologies Global Corp |
-0.36 4.21% |
8.20 | - | - | 356.02 | 2.19 | 130.34 | -5.20 |
| AVH Avita Medical Inc |
-0.08 1.73% |
4.55 | - | 9.97 | 9.59 | 7.17 | 6.76 | 15.37 |
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is based in Kingsgrove, Australia.
1 The Crescent, Kingsgrove, NSW, Australia, 2208
61 2 9541 0411
104
| Name | Title | Year Born |
|---|---|---|
| Mr. James S. McBrayer F.A.C.I.D., BSPharm, GDM, FAICD, AIM | CEO, MD, Company Sec. & Director | 1965 |
| Mr. Mathew Farag | Chief Operating Officer | NA |
| Mr. Graham N. Phillips | Fin. Mang. | NA |
| Dr. Mark Doverty | Global Head of Regulatory Compliance & Clinical Research | NA |
| Ms. Sally-Ann Cornelius | Head of Sales | NA |
| Ms. Niamh McAree | Head of Quality and Regulatory | NA |
| Mr. Chris Quinn | Head of Service | NA |
| Ms. Sui Ling Cheah | Financial Controller | 1970 |
| Mr. Lynn McLauchlin | Gen. Mang. of Canada | NA |
| Mr. Gary T. Somerville | Quality & Regulatory Mang. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...